Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Irritable Bowel Syndrome | Research article

Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways

Authors: Qiuke Hou, Yongquan Huang, Zhaoyang Zhu, Liu Liao, Xinlin Chen, Quanbin Han, Fengbin Liu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Tong-Xie-Yao-Fang (TXYF) has been shown to be effective in diarrhoea-predominant irritable bowel syndrome (IBS-D) patients. However, the underlying mechanism remains to be clarified. The aim of this study was to investigate the efficacy and related mechanisms of TXYF in an IBS-D rat model.

Methods

The IBS-D rat model was established with 4% acetic acid and evaluated by haematoxylin-eosin (HE) staining. Then, IBS-D rats were divided into control, TXYF and rifaximin groups and treated intragastrically with normal saline, TXYF and rifaximin, respectively, for 14 days. The following indicators were measured before and after treatment: defecation frequency, faecal water content (FWC) and colorectal distension (CRD). Histopathological changes in the distal colon were observed after treatment. The expression of OCLN and ZO1 in the distal colon of IBS-D rats reflected the intestinal mucosal permeability, as measured by qRT-PCR, western blot, and enzyme-linked immunosorbent assays (ELISAs). The NF-κB and Notch signalling pathways and inflammation-related factors were investigated.

Results

After treatment with TXYF, the defecation frequency, FWC and CRD were significantly lower than those in the model group (P < 0.05). HE staining showed that colonic epithelial cells (CECs) in the IBS-D rats displayed significant oedema, impaired intestinal mucosal integrity and an increased influx of inflammatory cells. A significant reduction in granulocyte and CEC oedema was observed after the administration of TXYF and rifaximin compared to that of the model group and blank group (P < 0.05). TXYF significantly upregulated the expression of OCLN and ZO-1 and downregulated inflammation-related factors (IL-6, IL-1β, and TNF-α and the chemokine KC) in IBS-D rats compared to those in the model group rats (P < 0.05). In terms of the NF-κB and Notch signalling pathways, the expression of NICD, p-ERK, Hes-1 and p-P65 decreased significantly in the TXYF and rifaximin groups, while the expression of ATOH1 increased significantly compared to that in the model group (P < 0.05).

Conclusion

TXYF can effectively improve intestinal permeability and enhance intestinal mucosal barrier function, which may be related to inhibition of the inflammatory cascade and the NF-κB and Notch signalling pathways.
Literature
1.
go back to reference Oshima T, Miwa H. Epidemiology of functional gastrointestinal disorders in Japan and in the world. J Neurogastroenterol Motil. 2015;21(3):320–9.CrossRef Oshima T, Miwa H. Epidemiology of functional gastrointestinal disorders in Japan and in the world. J Neurogastroenterol Motil. 2015;21(3):320–9.CrossRef
2.
go back to reference Chen C, Lu M, Pan Q, et al. Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One. 2015;10(12):e0145556.CrossRef Chen C, Lu M, Pan Q, et al. Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One. 2015;10(12):e0145556.CrossRef
3.
go back to reference Hou Q, Huang Y, Zhang C, et al. MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral Hyperalgesia in diarrhea-predominant irritable bowel syndrome rats. J Neurogastroenterol Motility. 2018;24(4):656–68.CrossRef Hou Q, Huang Y, Zhang C, et al. MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral Hyperalgesia in diarrhea-predominant irritable bowel syndrome rats. J Neurogastroenterol Motility. 2018;24(4):656–68.CrossRef
4.
go back to reference Hou Q, Huang Y, Zhu S, et al. MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1. Cell Physiol Biochem. 2017;44(6):2256–68.CrossRef Hou Q, Huang Y, Zhu S, et al. MiR-144 increases intestinal permeability in IBS-D rats by targeting OCLN and ZO1. Cell Physiol Biochem. 2017;44(6):2256–68.CrossRef
5.
go back to reference De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66(10):1748–60.CrossRef De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66(10):1748–60.CrossRef
6.
go back to reference Chang J, Leong RW, Wasinger VC, et al. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology. 2017;153(3):723–31.CrossRef Chang J, Leong RW, Wasinger VC, et al. Impaired intestinal permeability contributes to ongoing bowel symptoms in patients with inflammatory bowel disease and mucosal healing. Gastroenterology. 2017;153(3):723–31.CrossRef
7.
go back to reference Chen M, Tang TC, Wang Y, et al. Randomised clinical trial: Tong-Xie-Yao-fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(2):160–8.CrossRef Chen M, Tang TC, Wang Y, et al. Randomised clinical trial: Tong-Xie-Yao-fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(2):160–8.CrossRef
8.
go back to reference Pan F, Zhang T, Zhang YH, et al. Effect of Tongxie Yaofang granule in treating diarrhea-predominate irritable bowel syndrome. Chin J Integr Med. 2009;15(3):216–9.CrossRef Pan F, Zhang T, Zhang YH, et al. Effect of Tongxie Yaofang granule in treating diarrhea-predominate irritable bowel syndrome. Chin J Integr Med. 2009;15(3):216–9.CrossRef
9.
go back to reference Zheng L, Zhang YL, Dai YC, et al. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-kappaB activation. World J Gastroenterol. 2017;23(7):1180–8.CrossRef Zheng L, Zhang YL, Dai YC, et al. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-kappaB activation. World J Gastroenterol. 2017;23(7):1180–8.CrossRef
10.
go back to reference Lu L, Yan L, Yuan J, et al. Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. Chinas Med. 2018;13:6.CrossRef Lu L, Yan L, Yuan J, et al. Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. Chinas Med. 2018;13:6.CrossRef
11.
go back to reference Li B, Rui J, Ding X, et al. Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158–68.CrossRef Li B, Rui J, Ding X, et al. Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158–68.CrossRef
12.
go back to reference Wang FY, Su M, Zheng YQ, et al. Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacol Sin. 2015;36(6):708–15.CrossRef Wang FY, Su M, Zheng YQ, et al. Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacol Sin. 2015;36(6):708–15.CrossRef
13.
go back to reference Yin Y, Zhong L, Wang JW, et al. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J Gastroenterol. 2015;21(15):4536–46.CrossRef Yin Y, Zhong L, Wang JW, et al. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J Gastroenterol. 2015;21(15):4536–46.CrossRef
14.
go back to reference Ma X, Wang X, Kang N, et al. The effect of Tong-Xie-Yao-fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats. Evid Based Complement Alternat Med. 2017;2017:9086034.PubMedPubMedCentral Ma X, Wang X, Kang N, et al. The effect of Tong-Xie-Yao-fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats. Evid Based Complement Alternat Med. 2017;2017:9086034.PubMedPubMedCentral
15.
go back to reference Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell. 2007;128(3):445–58.CrossRef Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell. 2007;128(3):445–58.CrossRef
16.
go back to reference Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.CrossRef Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.CrossRef
17.
go back to reference Thakur ER, Shapiro J, Chan J, et al. A systematic review of the effectiveness of psychological treatments for IBS in gastroenterology settings: promising but in need of further study. Dig Dis Sci. 2018;63(9):2189–201.CrossRef Thakur ER, Shapiro J, Chan J, et al. A systematic review of the effectiveness of psychological treatments for IBS in gastroenterology settings: promising but in need of further study. Dig Dis Sci. 2018;63(9):2189–201.CrossRef
18.
go back to reference Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res. 2008;64(2):119–28.CrossRef Blanchard EB, Lackner JM, Jaccard J, et al. The role of stress in symptom exacerbation among IBS patients. J Psychosom Res. 2008;64(2):119–28.CrossRef
19.
go back to reference Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302.CrossRef Piche T. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302.CrossRef
20.
go back to reference Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075–83.CrossRef Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11(9):1075–83.CrossRef
21.
go back to reference Stevens BR, Goel R, Seungbum K, et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut. 2018;67(8):1555–7.CrossRef Stevens BR, Goel R, Seungbum K, et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut. 2018;67(8):1555–7.CrossRef
22.
go back to reference Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2018;0:1–15. Zeisel MB, Dhawan P, Baumert TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2018;0:1–15.
23.
go back to reference Gonzalez-Castro AM, Martinez C, Salvo-Romero E, et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. J Gastroenterol Hepatol. 2017;32(1):53–63.CrossRef Gonzalez-Castro AM, Martinez C, Salvo-Romero E, et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. J Gastroenterol Hepatol. 2017;32(1):53–63.CrossRef
24.
go back to reference Yan Z, Yang X, Wu J, et al. Qualitative and quantitative analysis of chemical constituents in traditional Chinese medicinal formula Tong-Xie-Yao-Fang by high-performance liquid chromatography/diode array detection/electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2011;691(1–2):110–8.CrossRef Yan Z, Yang X, Wu J, et al. Qualitative and quantitative analysis of chemical constituents in traditional Chinese medicinal formula Tong-Xie-Yao-Fang by high-performance liquid chromatography/diode array detection/electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2011;691(1–2):110–8.CrossRef
25.
go back to reference Shamshiri H, Paragomi P, Paydar MJ, et al. Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: the role of nitric oxide pathway. J Gastroenterol Hepatol. 2009;24(4):672–80.CrossRef Shamshiri H, Paragomi P, Paydar MJ, et al. Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: the role of nitric oxide pathway. J Gastroenterol Hepatol. 2009;24(4):672–80.CrossRef
26.
go back to reference Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.CrossRef Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9(12):874–85.CrossRef
27.
go back to reference Zheng X, Tsuchiya K, Okamoto R, et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17(11):2251–60.CrossRef Zheng X, Tsuchiya K, Okamoto R, et al. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis. 2011;17(11):2251–60.CrossRef
28.
go back to reference Pope JL, Bhat AA, Sharma A, et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of notch-signalling. Gut. 2014;63(4):622–34.CrossRef Pope JL, Bhat AA, Sharma A, et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of notch-signalling. Gut. 2014;63(4):622–34.CrossRef
29.
go back to reference Kovall RA, Gebelein B, Sprinzak D, et al. The canonical notch signaling pathway: structural and biochemical insights into shape, sugar, and force. Dev Cell. 2017;41(3):228–41.CrossRef Kovall RA, Gebelein B, Sprinzak D, et al. The canonical notch signaling pathway: structural and biochemical insights into shape, sugar, and force. Dev Cell. 2017;41(3):228–41.CrossRef
30.
go back to reference Zeng L, Li K, Wei H, et al. A novel EphA2 inhibitor exerts beneficial effects in PI-IBS in vivo and in vitro models via Nrf2 and NF-kappaB signaling pathways. Front Pharmacol. 2018;9:272.CrossRef Zeng L, Li K, Wei H, et al. A novel EphA2 inhibitor exerts beneficial effects in PI-IBS in vivo and in vitro models via Nrf2 and NF-kappaB signaling pathways. Front Pharmacol. 2018;9:272.CrossRef
31.
go back to reference Burbach BJ, Srivastava R, Medeiros RB, et al. Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP. J Immunol. 2008;181(7):4840–51.CrossRef Burbach BJ, Srivastava R, Medeiros RB, et al. Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP. J Immunol. 2008;181(7):4840–51.CrossRef
32.
go back to reference Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–42.CrossRef Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–42.CrossRef
Metadata
Title
Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways
Authors
Qiuke Hou
Yongquan Huang
Zhaoyang Zhu
Liu Liao
Xinlin Chen
Quanbin Han
Fengbin Liu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2749-4

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue